BMI 27-plus with established cardiovascular disease, where lowering heart-event risk is part of the reason to treat
While the medication offers undeniable physical benefits , the rapid transformation can cause unexpected psychological consequences , including anxiety, depression, heightened stress, obsessive-compulsive tendencies around food and exercise, and body dysmorphia
A single vial can represent a significant investment in your weight management research, and improper storage degrades that investment one molecule at a time
Beginning July 1, 2026, the Medicare GLP-1 Bridge Program may allow eligible Medicare Part D patients to access certain obesity-indicated GLP-1 medications, including Foundayo, Wegovy, and certain Zepbound formulations, for no more than $50 per month through December 31, 2027
The alternating hypothesis suggests that cycling between a pure GLP-1 agonist and a dual GIP/GLP-1 agonist could prevent or delay this tolerance